IQVIA (NYSE:IQV) and Genomics England today announced a collaboration to develop a platform that will connect clinical and de-identified genomics data to accelerate treatment advancements for patients. This alliance will enable faster and more efficient drug research, more robust evidence to support treatment value, and greater access to personalized medicines.
Using IQVIA’s E360 platform, authorized researchers will have privacy-protected, technology-enabled access to Genomics England’s patient-consented, de-identified data to create custom clinical-genomic datasets and run leading-edge analytics on genomics and observable traits.
Combining IQVIA’s leading real-world technologies and services experts with Genomics England’s datasets, network and infrastructure to generate, organize, and enhance genomic data, can make the United Kingdom one of the most attractive places for life sciences companies to invest. The deeper insights about patient populations and faster ability to understand the value of potential treatments could also make the UK a catalyst for analytic and scientific advances.
“IQVIA brings together deep healthcare and life sciences domain expertise to manage and curate real-world data with advanced analytical technologies. Working together, we can unlock the potential of these datasets to advance research and benefit patients in the UK as well as those throughout the world,” said Joanne Hackett, Genomics England’s, chief commercial officer.
Together, IQVIA and Genomics England will enable academic and commercial customers to conduct a wide range of research including: association studies of genomics and observable traits, comparative efficacy and safety trials, and burden-of-illness and discovery analytics using the de-identified data in a secure environment that protects patients’ privacy. Life sciences companies that use IQVIA’s leading clinical and observational research will be able to provide genomic testing to patients in parallel or as part of their clinical programs. This will help advance precision medicine and patients’ access to novel therapies – with the goal of delivering the right drugs to the right patients at the right time.
“Drawing insights from clinical-genomics datasets is the future of real-world research, and we are delighted to work alongside Genomics England as a pioneer in this evolving field,” said Jon Resnick, president, IQVIA Real-World and Analytics Solutions. “Our collaboration advances the analysis of these complex datasets, which could accelerate the discovery of precision therapies, improve access and health outcomes, and deliver upon our Human Data Science vision.”